Literature DB >> 15073599

Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation.

Vishwa Jeet Amatya1, Yukio Takeshima, Kouki Inai.   

Abstract

We have previously reported the statistically significant correlation of immunohistochemical expression of MIB-1 and p53 proteins among benign, atypical, and anaplastic meningiomas and p53 protein expression was high in atypical and anaplastic meningiomas. In the present study, we analyzed 22 cases of meningiomas for mutation of p53 gene in its spectrum of exon 5 to 8 using automated genetic analyzer. We did not find any mutation of p53 in any of these cases, thus suggesting the p53 protein expression is wild type. We analyzed 72 cases of meningiomas for determining the methylation status of p14(ARF) gene and the immunohistochemical expression of MDM2 protein to explain p53 protein expression in these meningiomas. We found methylation of p14(ARF) gene in five of 58 cases of benign meningiomas (8.6%), two of 10 cases of atypical meningiomas (20%), and two of four cases of anaplastic meningiomas (50%). In absence of p53 gene mutation, the high percentage of p14(ARF) gene methylation in high-grade meningioma may have been responsible for accumulation of wild-type p53 protein. In addition, we also found the loss of MDM2 protein in high-grade meningiomas. These deregulations of p14-MDM2-p53 pathway may contribute to the malignant progression of meningioma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073599     DOI: 10.1038/modpathol.3800111

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.

Authors:  Xun Zhang; Roger Gejman; Ali Mahta; Ying Zhong; Kimberley A Rice; Yunli Zhou; Pornsuk Cheunsuchon; David N Louis; Anne Klibanski
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.

Authors:  Adriana Olar; Khalida M Wani; Charmaine D Wilson; Gelareh Zadeh; Franco DeMonte; David T W Jones; Stefan M Pfister; Erik P Sulman; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2017-01-27       Impact factor: 17.088

3.  Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

Authors:  Anne Guyot; Mathilde Duchesne; Sandrine Robert; Anne-Sophie Lia; Paco Derouault; Erwan Scaon; Leslie Lemnos; Henri Salle; Karine Durand; François Labrousse
Journal:  J Neurooncol       Date:  2019-11-15       Impact factor: 4.130

Review 4.  Pathological classification and molecular genetics of meningiomas.

Authors:  Christian Mawrin; Arie Perry
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

Review 5.  Glioblastoma simultaneously present with adjacent meningioma: case report and review of the literature.

Authors:  Kengo Suzuki; Hiroyuki Momota; Akiko Tonooka; Hiroko Noguchi; Kouhei Yamamoto; Masahiko Wanibuchi; Yoshihiro Minamida; Tadashi Hasegawa; Kiyohiro Houkin
Journal:  J Neurooncol       Date:  2010-01-10       Impact factor: 4.130

6.  Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Tomislav Vladušić; Davor Tomas; Monika Logara; Josip Skoko; Reno Hrašćan
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

7.  A role for the p53 pathway in the pathology of meningiomas with NF2 loss.

Authors:  ZeNan Chang; Chin-Lin Guo; Iris Ahronowitz; Anat O Stemmer-Rachamimov; Mia MacCollin; Fabio P Nunes
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

Review 8.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.

Authors:  Peter Jun; Chibo Hong; Anita Lal; Judith M Wong; Michael W McDermott; Andrew W Bollen; Christoph Plass; William A Held; Dominic J Smiraglia; Joseph F Costello
Journal:  Neuro Oncol       Date:  2008-11-11       Impact factor: 12.300

10.  Hypermethylation of the 5' CpG island of the p14ARF flanking exon 1β in human colorectal cancer displaying a restricted pattern of p53 overexpression concomitant with increased MDM2 expression.

Authors:  Christine Nyiraneza; Christine Sempoux; Roger Detry; Alex Kartheuser; Karin Dahan
Journal:  Clin Epigenetics       Date:  2012-06-15       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.